Wall Street brokerages forecast that FibroGen Inc (NASDAQ:FGEN) will announce ($0.58) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for FibroGen’s earnings, with estimates ranging from ($0.68) to ($0.50). FibroGen posted earnings of ($0.48) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 20.8%. The firm is scheduled to announce its next earnings report on Monday, August 6th.
On average, analysts expect that FibroGen will report full year earnings of ($1.58) per share for the current financial year, with EPS estimates ranging from ($2.32) to ($1.00). For the next financial year, analysts expect that the business will report earnings of ($0.53) per share, with EPS estimates ranging from ($2.25) to $1.08. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow FibroGen.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.01. The business had revenue of $31.90 million for the quarter, compared to analysts’ expectations of $29.07 million. FibroGen had a negative net margin of 102.86% and a negative return on equity of 27.70%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.48) earnings per share.
Several analysts have commented on the stock. ValuEngine raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 21st. Mizuho reaffirmed a “buy” rating and issued a $74.00 price objective on shares of FibroGen in a research report on Tuesday, June 19th. Zacks Investment Research raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, June 15th. Finally, BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. FibroGen presently has a consensus rating of “Buy” and an average price target of $68.83.
In other news, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction that occurred on Thursday, April 5th. The shares were sold at an average price of $45.59, for a total value of $1,807,005.24. Following the sale, the chief executive officer now owns 2,950,813 shares of the company’s stock, valued at $134,527,564.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Roberto Pedro Rosenkranz sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 21st. The shares were sold at an average price of $63.65, for a total transaction of $63,650.00. Following the completion of the sale, the director now directly owns 33,700 shares in the company, valued at approximately $2,145,005. The disclosure for this sale can be found here. In the last ninety days, insiders sold 311,818 shares of company stock worth $16,320,411. Insiders own 8.96% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of FibroGen by 4.0% in the fourth quarter. BlackRock Inc. now owns 6,326,075 shares of the biopharmaceutical company’s stock valued at $299,855,000 after purchasing an additional 244,617 shares during the period. Farallon Capital Management LLC raised its position in shares of FibroGen by 3.6% in the first quarter. Farallon Capital Management LLC now owns 1,717,500 shares of the biopharmaceutical company’s stock valued at $79,349,000 after purchasing an additional 60,000 shares during the period. First Trust Advisors LP raised its position in shares of FibroGen by 1,058.4% in the fourth quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock valued at $36,813,000 after purchasing an additional 709,598 shares during the period. Geode Capital Management LLC raised its position in shares of FibroGen by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 723,869 shares of the biopharmaceutical company’s stock valued at $34,310,000 after purchasing an additional 2,312 shares during the period. Finally, Carillon Tower Advisers Inc. bought a new stake in shares of FibroGen in the fourth quarter valued at approximately $282,486,000. 63.07% of the stock is currently owned by institutional investors.
FGEN stock traded down $0.50 during mid-day trading on Wednesday, hitting $60.85. The company had a trading volume of 432,461 shares, compared to its average volume of 548,934. The firm has a market cap of $5.30 billion, a price-to-earnings ratio of -35.17 and a beta of 1.95. The company has a debt-to-equity ratio of 0.19, a quick ratio of 8.61 and a current ratio of 8.61. FibroGen has a 12 month low of $30.95 and a 12 month high of $65.00.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Get a free copy of the Zacks research report on FibroGen (FGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.